Pattern of Failure and Treatment Results in Triple Negative Breast Cancer Patients

Abstract

Non metastatic patients (n=108) had median follow up duration of 3.5 years. 21.3% patients developed relapse with median time to relapse of 11 months. 78.3% of relapsed patients had visceral (88.3% lung) metastasis, 13% bone metastasis, 21.7% brain metastasis and 13% LRR. Predictor for relapse: Significantly high risk of relapse in patients with large tumor size [T4: 66.75%, T3: 22.9%, T2:16.7%, T1: 0% (p= 0.002)], positive LNs [N3: 100%, N2: 37.9%, N1: 15.1%, N0: 4.3% (p <0.001)] and Ki67 [> 20: 31.6% versus 10.8% for Ki67≤ 20 (P =0.007)]. Multivariate analysis revealed only T4 and N2-3 were significantly associated with high probability for relapse (P = 0.022 & 0.038, respectively). Tumor grade I 1(0.9) 0 1(0.8) II 41(38.0) 7(35.0) 48(37.5) III 66(61.1) 13(65.0) 79(61.7) histopathology IDC 94(87.1) 13(65.0) 107(83.6) ILC 8(7.4) 1(5.0) 9(7.0) Others 6(5.5) 6(30.0) 12(9.4) surgery MRM 71(65.7) 0 BCS 37(34.3) 0 ALND 100(92.6) 0 SLN 8(7.4) 0 Neo adjuvant chemotherapy 34/108 (31.5%) CR 6(17.6%) PR 24(70.6%) No response 4(11.8%) Types of chemotherapy FAC 14(12.9%) 14 (11%) AC and Taxol 94(87%) 20 (100%) 114 (89%) Platinum/Gem 0(0%) 20(100%) 20(15.6%) Taxotere 0(0%) 12(60%) Xeloda 0(0%) 6(30%) Adjuvant XRT NO 10(9.3%) 20 (100%) 30(23.4%) conventional 56(51.8%) 0 56(43.8%) hypofractionation 42(38.9%) 0 42(32.8%) K. M Curve for DFS among non metastatic TNBC.